SCHEMBL4586751

SCHEMBL4586751

CCOC(=O)CC=S

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6647774 0.79 GAA (0.57)
SCHEMBL6708068 0.79 GAA (0.57)
SCHEMBL6082087 0.79 DGKA (0.34)
SCHEMBL18328192 0.78 ATM (0.52)
SCHEMBL82647 0.77
SCHEMBL1986853 0.77
SCHEMBL8972782 0.77
SCHEMBL11719772 0.76
SCHEMBL5959111 0.75 NAAA (0.41)
SCHEMBL9800037 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5583235-A ALKENYLATION, CYCLIZATION SHAMAN PHARMACEUTICALS, INC. (US) 1996-12-10 US claimed
CN-118924913-A Novel camptothecin analogue ligand-drug conjugate, intermediate, pharmaceutical composition and application thereof 上海盟科药业股份有限公司 2024-11-12 CN disclosed
CN-113840603-B Pyrimidine five-membered nitrogen heterocyclic derivative, preparation method and medical application thereof 上海拓界生物医药科技有限公司 2024-08-13 CN disclosed
CN-116669734-A Crystal form of pyrimido five-membered nitrogen heterocyclic derivative and preparation method thereof 江苏恒瑞医药股份有限公司 2023-08-29 CN disclosed
US-20220380385-A1 PYRIMIDINE FIVE-MEMBERED NITROGEN HETEROCYCLIC DERIVATIVE, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF TUOJIE BIOTECH(SHANGHAI) CO., LTD. (CN) 2022-12-01 US disclosed
WO-2022135568-A1 CRYSTAL FORM OF PYRIMIDO FIVE-MEMBERED NITROGEN HETEROCYCLIC DERIVATIVE AND PREPARATION METHOD THEREFOR 江苏恒瑞医药股份有限公司 2022-06-30 WO disclosed
EP-3991731-A1 PYRIMIDINE FIVE-MEMBERED NITROGEN HETEROCYCLIC DERIVATIVE, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF Tuojie Biotech (Shanghai) Co., Ltd. (CN) 2022-05-04 EP disclosed
US-20120244182-A1 USE OF TRYPTANTHRIN COMPOUNDS FOR IMMUNE POTENTIATION NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2012-09-27 US disclosed
EP-1594524-B1 USE OF TRYPTANTHRIN COMPOUNDS FOR IMMUNE POTENTIATION NOVARTIS VACCINES & DIAGNOSTIC (US) 2012-08-15 EP disclosed
US-8193185-B2 Administering a tryptanthrin compound, e.g., 8-nitroindolo[2,1-b]quinazoline-6,12-dione, to potentiate the immune response to an antigen; immunostimulants; small molecule immune potentiators; immunotherapy for infectious diseases; anticarcinogenic agents; vaccine adjuvant compositions and kits NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2012-06-05 US disclosed
EP-0429464-B1 BIVALENT LIGANDS EFFECTIVE FOR BLOCKING ACAT ENZYME UPJOHN CO (US) 1994-11-23 EP disclosed
US-5304548-A Tether composition joining two furochromones THE UPJOHN COMPANY (US) 1994-04-19 US disclosed
EP-0525123-A1 ANTIATHEROSCLEROTIC AND ANTITHROMBOTIC 1-BENZOPYRAN-4-ONES AND 2-AMINO-1,3-BENZOXAZINE-4-ONES. UPJOHN CO (US) 1993-02-03 EP disclosed
US-5180717-A Atherosclerosis treatment and antilipemic agents THE UPJOHN COMPANY (US) 1993-01-19 US disclosed
WO-1991019707-A2 ANTIATHEROSCLEROTIC AND ANTITHROMBOTIC 1-BENZOPYRAN-4-ONES AND 2-AMINO-1,3-BENZOXAZINE-4-ONES THE UPJOHN COMPANY (US) 1991-12-26 WO disclosed
EP-0459983-A1 ANTIATHEROSCLEROTIC AND ANTITHROMBOTIC 1-BENZOPYRAN-4-ONES AND 2-AMINO-1,3-BENZOXAZINE-4-ONES PHARMACIA &amp; UPJOHN COMPANY (US) 1991-12-11 EP disclosed
EP-0429464-A1 BIVALENT LIGANDS EFFECTIVE FOR BLOCKING ACAT ENZYME. UPJOHN CO (US) 1991-06-05 EP disclosed
WO-1990006921-A1 ANTIATHEROSCLEROTIC AND ANTITHROMBOTIC 1-BENZOPYRAN-4-ONES AND 2-AMINO-1,3-BENZOXAZINE-4-ONES THE UPJOHN COMPANY (US) 1990-06-28 WO disclosed
WO-1990002129-A1 BIVALENT LIGANDS EFFECTIVE FOR BLOCKING ACAT ENZYME THE UPJOHN COMPANY (US) 1990-03-08 WO disclosed
US-4067988-A 3-Phenyl-1,2,4-oxadiazole derivatives as antiinflammatory-antitussive agents LABORATOIRES CASSENNE (FR) 1978-01-10 US disclosed